- Barriers to treatment of failed or interferon ineligible patients in the era of DAA: single center study
-
Seo KI, Yun BC, Li WJ, Lee SU, Han BH, Park ET
- KMID: 2412117
- Clin Mol Hepatol.
- 2017 Mar;23(1):74-79.
- doi: 10.3350/cmh.2016.0052
BACKGROUND/AIMS: Interferon-based treatment is not appropriate for a large number of patients with chronic hepatitis C for various medical and social reasons. Newly developed directly acting antivirals (DAAs) have been... -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy and safety of daclatasvir plus asunaprevir for Korean patients with HCV genotype Ib infection: a retrospective multi-institutional study
-
Cho BW, Kim SB, Song IH, Lee SH, Kim HS, Lee TH, Kang YW, Kim SH, Lee BS, Chae HB
- KMID: 2412114
- Clin Mol Hepatol.
- 2017 Mar;23(1):51-56.
- doi: 10.3350/cmh.2016.0053
BACKGROUND/AIMS: The combination of daclatasvir (DCV) and asunaprevir (ASV) has demonstrated a high sustained virologic response at 12 weeks (SVR12) and a low rate of adverse events in previous clinical... -
- CITED
-
- Close
- SHARE
-
- Close
- Immunosuppression status of liver transplant recipients with hepatitis C affects biopsy-proven acute rejection
-
Kim JM, Lee KW, Song GW, Jung BH, Lee HW, Yi NJ, Kwon CD, Hwang S, Suh KS, Joh JW, Lee SK, Lee SG
- KMID: 2373137
- Clin Mol Hepatol.
- 2016 Sep;22(3):366-371.
- doi: 10.3350/cmh.2016.0022
BACKGROUND/AIMS: The relationship between patient survival and biopsy-proven acute rejection (BPAR) in liver transplant recipients with hepatitis C remains unclear. The aims of this study were to compare the characteristics... -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy and safety of daclatasvir and asunaprevir for hepatitis C virus genotype 1b infection
-
Nam HC, Lee HL, Yang H, Song MJ
- KMID: 2373122
- Clin Mol Hepatol.
- 2016 Jun;22(2):259-266.
- doi: 10.3350/cmh.2016.0020
BACKGROUND/AIMS: The treatment strategy for hepatitis C virus (HCV) has been changing rapidly since the introduction of direct-acting antivirals such as daclatasvir (DCV) and asunaprevir (ASV). We evaluated the efficacy... -
- CITED
-
- Close
- SHARE
-
- Close
- KASL clinical practice guidelines: management of hepatitis C
-
The Korean Association for the Study of the Liver (KASL)
- KMID: 2363030
- Clin Mol Hepatol.
- 2016 Mar;22(1):76-139.
- doi: 10.3350/cmh.2016.22.1.76
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Sofosbuvir-based therapy for patients with chronic hepatitis C: Early experience of its efficacy and safety in Korea
-
Cho Y, Cho EJ, Lee JH, Yu SJ, Yoon JH, Kim YJ
- KMID: 2359817
- Clin Mol Hepatol.
- 2015 Dec;21(4):358-364.
- doi: 10.3350/cmh.2015.21.4.358
BACKGROUND/AIMS: The previous standard treatment for chronic hepatitis C (CHC) patients, comprising a combination of pegylated interferon (IFN) and ribavirin, was associated with suboptimal efficacy and severe adverse reactions. A... -
- CITED
-
- Close
- SHARE
-
- Close
- The CD4 slope can be a predictor of immunologic recovery in advanced HIV patients: a case-control study
-
Kim KH, Yi J, Lee SH
- KMID: 2381569
- Korean J Intern Med.
- 2015 Sep;30(5):705-713.
- doi: 10.3904/kjim.2015.30.5.705
BACKGROUND/AIMS: Advanced human immunodeficiency virus (HIV) infection, despite sustained viral suppression by highly active antiretroviral therapy (HAART), is a risk factor for poor immunologic recovery. However, some patients with advanced... -
- CITED
-
- Close
- SHARE
-
- Close
- Highly effective peginterferon alpha-2a plus ribavirin combination therapy for chronic hepatitis C in hemophilia in Korea
-
Yang SY, Lee HW, Lee YJ, Park SJ, Yoo KY, Kim HJ
- KMID: 2164362
- Clin Mol Hepatol.
- 2015 Jun;21(2):125-130.
- doi: 10.3350/cmh.2015.21.2.125
BACKGROUND/AIMS: Chronic hepatitis C (CHC) is a major comorbidity in patients with hemophilia. However, there are no published data on the efficacy of antiviral therapy in Korea. We assessed the... -
- CITED
-
- Close
- SHARE
-
- Close
- Predictors of spontaneous viral clearance and outcomes of acute hepatitis C infection
-
Cho YK, Kim YN, Song BC
- KMID: 2070255
- Clin Mol Hepatol.
- 2014 Dec;20(4):368-375.
- doi: 10.3350/cmh.2014.20.4.368
BACKGROUND/AIMS: This study evaluated the predictors of spontaneous viral clearance (SVC), as defined by two consecutive undetectable hepatitis C virus (HCV) RNA tests performed > or =12 weeks apart, and... -
- CITED
-
- Close
- SHARE
-
- Close
- A Polymorphism in the Microsomal Triglyceride Transfer Protein Can Predict the Response to Antiviral Therapy in Egyptian Patients with Chronic Hepatitis C Virus Genotype 4 Infection
-
Saad Y, Shaker O, Nassar Y, Ahmad L, Said M, Esmat G
- KMID: 2070084
- Gut Liver.
- 2014 Nov;8(6):655-661.
- doi: 10.5009/gnl13374
BACKGROUND/AIMS: A polymorphism in the microsomal triglyceride transfer protein (MTP) is associated with hepatic fibrosis, and carriers showed higher levels of steatosis, higher levels of hepatitis C virus (HCV) RNA... -
- CITED
-
- Close
- SHARE
-
- Close
- KASL clinical practice guidelines: Management of Hepatitis C
-
The Korean Association for the Study of the Liver (KASL)
- KMID: 1788561
- Clin Mol Hepatol.
- 2014 Jun;20(2):89-136.
- doi: 10.3350/cmh.2014.20.2.89
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Clinical and epidemiological characteristics of Korean patients with hepatitis C virus genotype 6
-
Seong MH, Kil H, Kim JY, Lee SS, Jang ES, Kim JW, Jeong SH, Kim YS, Bae SH, Lee YJ, Lee HC, Yun H, Kang BH, Kim K
- KMID: 1493574
- Clin Mol Hepatol.
- 2013 Mar;19(1):45-50.
- doi: 10.3350/cmh.2013.19.1.45
BACKGROUND/AIMS: The distribution of hepatitis C virus (HCV) genotypes varies geographically. In Korea, genotypes 1 and 2 comprise more than 90% of HCV infections, while genotype 6 is very rare.... -
- CITED
-
- Close
- SHARE
-
- Close
- Serum bilirubin levels are inversely associated with nonalcoholic fatty liver disease
-
Kwak MS, Kim D, Chung GE, Kang SJ, Park MJ, Kim YJ, Yoon JH, Lee HS
- KMID: 1410895
- Clin Mol Hepatol.
- 2012 Dec;18(4):383-390.
- doi: 10.3350/cmh.2012.18.4.383
BACKGROUND/AIMS: Serum bilirubin exerts antioxidant and cytoprotective effects. In addition, elevated serum bilirubin levels are associated with a decreased risk of metabolic and cardiovascular diseases. However, few studies have evaluated... -
- CITED
-
- Close
- SHARE
-
- Close
- Coinfection of hepatitis A virus genotype IA and IIIA complicated with autoimmune hemolytic anemia, prolonged cholestasis, and false-positive immunoglobulin M anti-hepatitis E virus: a case report
-
Kim HS, Jeong SH, Jang JH, Myung HJ, Kim JW, Bang SM, Song SH, Kim H, Yun HS
- KMID: 1792612
- Korean J Hepatol.
- 2011 Dec;17(4):323-327.
- doi: 10.3350/kjhep.2011.17.4.323
A 37-year-old male presented with fever and jaundice was diagnosed as hepatitis A complicated with progressive cholestasis and severe autoimmune hemolytic anemia. He was treated with high-dose prednisolone (1.5 mg/kg),... -
- CITED
-
- Close
- SHARE
-
- Close
- Peginterferon alpha and ribavirin combination therapy in patients with hepatitis C virus-related liver cirrhosis
-
Kim KH, Jang BK, Chung WJ, Hwang JS, Kweon YO, Tak WY, Lee HJ, Lee CH, Suh JI
- KMID: 1025202
- Korean J Hepatol.
- 2011 Sep;17(3):220-225.
- doi: 10.3350/kjhep.2011.17.3.220
BACKGROUND/AIMS: Pegylated interferon (peginterferon) and ribavirin combination therapy is less effective and associated with a higher frequency of serious complications in chronic hepatitis C patients with cirrhosis than in noncirrhotic... -
- CITED
-
- Close
- SHARE
-
- Close
- Durability of Sustained Virologic Response in Chronic Hepatitis C: Analysis of Factors Related to Relapse after Sustained Virologic Response with Peginterferon Plus Ribavirin Combination Therapy
-
Lee JE, Yoon NR, Kim JD, Song MJ, Kwon JH, Bae SH, Choi JY, Jeong SW, Yoon SK
- KMID: 1128356
- Korean J Gastroenterol.
- 2011 Mar;57(3):173-179.
- doi: 10.4166/kjg.2011.57.3.173
BACKGROUND/AIMS: Pegylated interferon plus ribavirin combination therapy has been the standard of therapy for patients with chronic hepatitis C. Although previous studies have reported long term durability after the sustained... -
- CITED
-
- Close
- SHARE
-
- Close
- Evaluation of ARCHITECT HCV Core Antigen Assay
-
Song D, Kang JE, Kim SY, Hwang SH, Kim HH, Lee EY, Son HC
- KMID: 1781673
- Korean J Lab Med.
- 2010 Dec;30(6):654-659.
- doi: 10.3343/kjlm.2010.30.6.654
BACKGROUND: Hepatitis C virus (HCV) core antigen (Ag) levels are known to be well correlating with HCV RNA levels, and may be used as an alternative marker of HCV replication... -
- CITED
-
- Close
- SHARE
-
- Close
- 24 Weeks Treatment with Pegylated Interferon Alfa Plus Ribavirin May Be Possible in Genotype 1 Chronic Hepatitis C Patients with Rapid Virological Response Who Have Low Pretreatment Viremia
-
Moon SS, Kang HG, Seo JA, Jung EU, Lee SH, Park SJ, Lee YJ, Seol SY
- KMID: 1775876
- Korean J Gastroenterol.
- 2010 Jul;56(1):33-38.
- doi: 10.4166/kjg.2010.56.1.33
BACKGROUND/AIMS: The standard treatment for chronic hepatitis C infected with hepatitis C virus (HCV) genotype 1 is a combination of pegylated interferon alfa and ribavirin over a 48 weeks period.... -
- CITED
-
- Close
- SHARE
-
- Close
- Clinical efficacy and safety of the combination therapy of peginterferon alpha and ribavirin in cirrhotic patients with HCV infection
-
Cheong HR, Woo HY, Heo J, Yoon KT, Kim DU, Kim GH, Kang DH, Song GA, Cho M
- KMID: 1782219
- Korean J Hepatol.
- 2010 Mar;16(1):38-48.
- doi: 10.3350/kjhep.2010.16.1.38
BACKGROUND/AIMS: The combination therapy of peginterferon (PEG-IFN) and ribavirin is the standard treatment for hepatitis C virus (HCV) infection. However, few trials have involved patients with cirrhosis. The purpose of... -
- CITED
-
- Close
- SHARE
-
- Close
- A comparison of 24- vs. 48-week peginterferon plus ribavirin in patients with genotype 1 chronic hepatitis C
-
Kim MN, Yoon KT, Park JY, Kim DY, Ahn SH, Chon CY, Han KH
- KMID: 1384057
- Korean J Hepatol.
- 2009 Dec;15(4):496-503.
- doi: 10.3350/kjhep.2009.15.4.496
BACKGROUND/AIMS: The standard therapy for patients with genotype 1 chronic hepatitis C (CHC) is a combination of peginterferon and ribavirin for 48 weeks. However, the most appropriate duration of treatment... -
- CITED
-
- Close
- SHARE
-
- Close
